Online inquiry

IVTScrip™ mRNA-Human ATP1B4, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK25788MR)

This product GTTS-WK25788MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the ATP1B4 protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001142447.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 23439
UniProt ID Q9UN42
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ATP1B4, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WK25788MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK19182MR IVTScrip™ mRNA-Human AP2-gamma, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AP2-gamma
GTTS-WK24339MR IVTScrip™ mRNA-Human APOO, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA APOO
GTTS-WK11098MR IVTScrip™ mRNA-Human AGFG2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGFG2
GTTS-WK23136MR IVTScrip™ mRNA-Human APOL6, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APOL6
GTTS-WK24946MR IVTScrip™ mRNA-Human AQP1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AQP1
GTTS-WK0739MR IVTScrip™ mRNA-Human CRIP1, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CRIP1
GTTS-WK21871MR IVTScrip™ mRNA-Human ATOX1, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ATOX1
GTTS-WK17875MR IVTScrip™ mRNA-Human Androgen-binding protein, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Androgen-binding protein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW